Cannabis Sativa: A Budding Therapy for Dementia

About Webinar

In this comprehensive session, A/Prof Steiner-Lim will delve into the looming problem of dementia as a leading cause of disability in Australians aged 65 years and over, and the urgency of finding new therapeutic solutions given the high failure rate of Alzheimer’s disease drugs.

She will explain the potential therapeutic properties of Cannabis sativa L., which contains over 100 phytocannabinoids and other compounds that may help address multiple aspects of dementia pathophysiology and assist with clinical management. Furthermore, she will provide an overview of the current preclinical and clinical evidence on medicinal cannabis for dementia, underscoring the potential of this plant as a novel approach to dementia therapy.

The session will also discuss her team's innovative approach to a new clinical trial using a CBD-rich cannabis formulation as a potential solution for early-stage Alzheimer’s disease.

Learning Outcomes

Understanding Dementia: Gain insights into the looming problem of dementia and understand its impact as a leading cause of disability in Australians aged 65 years and over.
Therapeutic Properties of Cannabis: Learn about the potential therapeutic properties of Cannabis sativa L. and how it may address multiple aspects of dementia pathophysiology and assist with clinical management.
Current Evidence on Medicinal Cannabis: Explore the current preclinical and clinical evidence on medicinal cannabis for dementia and understand its potential as a novel approach to dementia therapy.
Innovative Clinical Trials: Understand the innovative approach to new clinical trials using a CBD-rich cannabis formulation as a potential solution for early-stage Alzheimer’s disease.

Associate Professor Genevieve Steiner-Lim, an NHMRC Emerging Leadership Fellow and the Clinical Research Platform Lead at NICM Health Research Institute, has dedicated her career to the early detection, prevention, and treatment of cognitive decline in older adults. Her ultimate aim is to reduce the risk of dementia and improve the quality of life for this population.

A/Prof Steiner-Lim is currently involved in groundbreaking research testing novel therapeutics for early-stage Alzheimer’s disease intervention, including a world-first medicinal cannabis trial.

On-demand Webinar

Subscribe to our Free Plan and gain access to this on-demand webinar plus four more, at no cost.

Webinar details

Claim 1 CPD hour

1 hour of recorded content

Statement of Attendance

Claim 1 CPD Hour

Medihuanna is a CPD approved education provider, and this activity has been approved by the RACGP (Activity ID: 518521). Upon completing this activity, you will be eligible to claim CPD hours. The activity will include the following CPD allocation which will be uploaded to the RACGP dashboard.

cpd_hours